BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24458115)

  • 1. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder.
    Izawa S; Funaki Y; Iida A; Tokudome K; Tamura Y; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2014; 89(1):61-7. PubMed ID: 24458115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring.
    Kawamura O; Hosaka H; Shimoyama Y; Kawada A; Kuribayashi S; Kusano M; Yamada M
    Digestion; 2015; 91(1):19-25. PubMed ID: 25632912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
    Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impedance-high resolution manometry analysis of patients with nonerosive reflux disease.
    Ribolsi M; Holloway RH; Emerenziani S; Balestrieri P; Cicala M
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):52-7. PubMed ID: 23891920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
    Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
    Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
    Pace F; Pace M
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-hour ambulatory pH-metry in patients with refractory heartburn: a prospective study.
    Talaie R; Forootan M; Donboli K; Dadashzadeh N; Sadeghi A; Poorsaadat S; Moghimi B; Mohammad Alizadeh AH; Zali MR
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):11-5. PubMed ID: 19337627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn.
    Kandulski A; Weigt J; Caro C; Jechorek D; Wex T; Malfertheiner P
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1075-81. PubMed ID: 25496815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.
    Viazis N; Karamanolis GP; Anastasiou J; Keyoglou A; Vlachogiannakos J; Ladas SD; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1450-5. PubMed ID: 24047861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia?
    Bashashati M; Hejazi RA; Andrews CN; Storr MA
    Can J Gastroenterol Hepatol; 2014 Jun; 28(6):335-41. PubMed ID: 24719900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of gastro-esophageal reflux disease in patients with difficult to control asthma and effect of proton pump inhibitor therapy on asthma symptoms, reflux symptoms, pulmonary function and requirement for asthma medications.
    Sandur V; Murugesh M; Banait V; Rathi PM; Bhatia SJ; Joshi JM; Kate A
    J Postgrad Med; 2014; 60(3):282-6. PubMed ID: 25121368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cough and gastroesophageal reflux: from the gastroenterologist end.
    Pauwels A; Blondeau K; Dupont L; Sifrim D
    Pulm Pharmacol Ther; 2009 Apr; 22(2):135-8. PubMed ID: 19063984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
    Iwakiri K; Sano H; Tanaka Y; Kawami N; Umezawa M; Futagami S; Hoshihara Y; Nomura T; Miyashita M; Sakamoto C
    Digestion; 2010; 82(3):156-61. PubMed ID: 20588027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.